Skip to Main Content

Author Details

Stephen B Baylin
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University
1963
509
152
Prashant Mali (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36928921A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.Clin Cancer Res2023
38076862SARS-CoV-2 Orphan Gene ORF10 Contributes to More Severe COVID-19 Disease.medRxiv2023
37556555Core mitochondrial genes are down-regulated during SARS-CoV-2 infection of rodent and human hosts.Sci Transl Med2023
37456850Derivation of CD8<sup>+</sup> T cell infiltration potentiators in non-small-cell lung cancer through tumor microenvironment analysis.iScience2023
37125438The legacy is not just with you: an interview with Stephen Baylin.Epigenomics2023
37249603Oncogenic Transformation Drives DNA Methylation Loss and Transcriptional Activation at Transposable Element Loci.Cancer Res2023
36928921A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy.Clin Cancer Res2023
37487069Transcription factor expression repertoire basis for epigenetic and transcriptional subtypes of colorectal cancers.Proc Natl Acad Sci U S A2023
37487069Transcription factor expression repertoire basis for epigenetic and transcriptional subtypes of colorectal cancers.Proc Natl Acad Sci U S A2023
38076862SARS-CoV-2 Orphan Gene ORF10 Contributes to More Severe COVID-19 Disease.medRxiv2023
37556555Core mitochondrial genes are down-regulated during SARS-CoV-2 infection of rodent and human hosts.Sci Transl Med2023
37125438The legacy is not just with you: an interview with Stephen Baylin.Epigenomics2023
37456850Derivation of CD8<sup>+</sup> T cell infiltration potentiators in non-small-cell lung cancer through tumor microenvironment analysis.iScience2023
37249603Oncogenic Transformation Drives DNA Methylation Loss and Transcriptional Activation at Transposable Element Loci.Cancer Res2023
35233572TARGETED DOWN REGULATION OF CORE MITOCHONDRIAL GENES DURING SARS-COV-2 INFECTION.bioRxiv2022
35838045Inhibiting DNA methylation improves antitumor immunity in ovarian cancer.J Clin Invest2022
35759659Activating STING1-dependent immune signaling in <i>TP53</i> mutant and wild-type acute myeloid leukemia.Proc Natl Acad Sci U S A2022
36222848Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine.Clin Cancer Res2022
35884401Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer Cells.Cancers (Basel)2022
35664076The interplay between lncRNAs, RNA-binding proteins and viral genome during SARS-CoV-2 infection reveals strong connections with regulatory events involved in RNA metabolism and immune response.Theranostics2022
35233572TARGETED DOWN REGULATION OF CORE MITOCHONDRIAL GENES DURING SARS-COV-2 INFECTION.bioRxiv2022
35091444Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia.Clin Cancer Res2022
35074468Betacoronavirus-specific alternate splicing.Genomics2022
35838045Inhibiting DNA methylation improves antitumor immunity in ovarian cancer.J Clin Invest2022
35759659Activating STING1-dependent immune signaling in <i>TP53</i> mutant and wild-type acute myeloid leukemia.Proc Natl Acad Sci U S A2022
35664076The interplay between lncRNAs, RNA-binding proteins and viral genome during SARS-CoV-2 infection reveals strong connections with regulatory events involved in RNA metabolism and immune response.Theranostics2022
35884401Selective CDK9 Inhibition by Natural Compound Toyocamycin in Cancer Cells.Cancers (Basel)2022
36222848Safety, Outcomes, and T-Cell Characteristics in Patients with Relapsed or Refractory MDS or CMML Treated with Atezolizumab in Combination with Guadecitabine.Clin Cancer Res2022
35074468Betacoronavirus-specific alternate splicing.Genomics2022
35091444Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia.Clin Cancer Res2022
33471554Interview with Stephen B Baylin.Epigenomics2021
34230929Betacoronavirus-specific alternate splicing.bioRxiv2021
33632774Bacterial-Driven Inflammation and Mutant <i>BRAF</i> Expression Combine to Promote Murine Colon Tumorigenesis That Is Sensitive to Immune Checkpoint Therapy.Cancer Discov2021
33471554Interview with Stephen B Baylin.Epigenomics2021
33948587The Great Deceiver: miR-2392's Hidden Role in Driving SARS-CoV-2 Infection.bioRxiv2021
34680341Clinical Significance of Plasma CD9-Positive Exosomes in HIV Seronegative and Seropositive Lung Cancer Patients.Cancers (Basel)2021
34624208Role of miR-2392 in driving SARS-CoV-2 infection.Cell Rep2021
34788629Evaluating the impact of age on immune checkpoint therapy biomarkers.Cell Rep2021
34433584Epigenetic Therapies in Ovarian Cancer Alter Repetitive Element Expression in a <i>TP53</i>-Dependent Manner.Cancer Res2021
34433020Evaluating the impact of age on immune checkpoint therapy biomarkers.Cell Rep2021
33632774Bacterial-Driven Inflammation and Mutant <i>BRAF</i> Expression Combine to Promote Murine Colon Tumorigenesis That Is Sensitive to Immune Checkpoint Therapy.Cancer Discov2021
34433584Epigenetic Therapies in Ovarian Cancer Alter Repetitive Element Expression in a <i>TP53</i>-Dependent Manner.Cancer Res2021
34788629Evaluating the impact of age on immune checkpoint therapy biomarkers.Cell Rep2021
34433020Evaluating the impact of age on immune checkpoint therapy biomarkers.Cell Rep2021
34624208Role of miR-2392 in driving SARS-CoV-2 infection.Cell Rep2021
34680341Clinical Significance of Plasma CD9-Positive Exosomes in HIV Seronegative and Seropositive Lung Cancer Patients.Cancers (Basel)2021
34230929Betacoronavirus-specific alternate splicing.bioRxiv2021
33948587The Great Deceiver: miR-2392's Hidden Role in Driving SARS-CoV-2 Infection.bioRxiv2021
31548600The emerging role of epigenetic therapeutics in immuno-oncology.Nat Rev Clin Oncol2020
32302562Epigenetic Therapy for Epithelioid Sarcoma.Cell2020
  • 1 - 50 of 1,018

Recommended Authors

David Klinkebiel
University of Nebraska Medical Center
Career Start Year 2005
Number of shared co-authors 1
Anderly C Chueh
Biomedicine Discovery Institute, Monash University
Career Start Year 2005
Number of shared co-authors 2
Duncan Sproul
Institute of Genetics and Cancer, University of Edinburgh
Career Start Year 2004
Number of shared co-authors 0
Robert Brown
Ovarian Cancer Action Research Centre, Imperial College London
Career Start Year 2002
Number of shared co-authors 15
Yonghong Wang
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 2001
Number of shared co-authors 3
Jonathan K Killian
From Foundation Medicine
Career Start Year 1999
Number of shared co-authors 4
Tim H-M Huang
University of Texas Health San Antonio (UTHSA)
Career Start Year 1997
Number of shared co-authors 4
Robert L Walker
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1997
Number of shared co-authors 11
Otavia L Caballero
Ludwig Institute for Cancer Research Ltd.
Career Start Year 1993
Number of shared co-authors 6
Charles De Smet
de Duve Institute, Universite catholique de Louvain
Career Start Year 1992
Number of shared co-authors 1
Thomas J Giordano
University of Michigan ann arbor
Career Start Year 1989
Number of shared co-authors 60
Robyn L Ward
University of Sydney
Career Start Year 1989
Number of shared co-authors 7
Bharati Bapat
Mt Sinai Hospital
Career Start Year 1988
Number of shared co-authors 4
David S Schrump
Center for Cancer Research, National Cancer Institute
Career Start Year 1988
Number of shared co-authors 3
Kristian Helin
The Institute of Cancer Research
Career Start Year 1988
Number of shared co-authors 4
Martin J Walsh
Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai
Career Start Year 1987
Number of shared co-authors 2
Wan L Lam
British Columbia Cancer Research Institute
Career Start Year 1987
Number of shared co-authors 12
Frederick E Domann
University of Iowa
Career Start Year 1986
Number of shared co-authors 0
Richard R Meehan
Institute of Genetics and Molecular Medicine, University of Edinburgh
Career Start Year 1984
Number of shared co-authors 0
Ann M Killary
The University of Texas M. D. Anderson Cancer Center
Career Start Year 1984
Number of shared co-authors 5
Francisco X Real
Spanish National Cancer Research Centre-CNIO
Career Start Year 1983
Number of shared co-authors 10
Edison T Liu
USA The Jackson Laboratory Cancer Center
Career Start Year 1982
Number of shared co-authors 8
Christoph Plass
German Cancer Research Center
Career Start Year 1982
Number of shared co-authors 15
David M Thomas
Garvan Institute of Medical Research
Career Start Year 1980
Number of shared co-authors 8
David J Adams
Wellcome Sanger Institute
Career Start Year 1980
Number of shared co-authors 12
Chi V Dang
Johns Hopkins University School of Medicine
Career Start Year 1978
Number of shared co-authors 24
Colin S Cooper
Norwich Medical School, University of East Anglia
Career Start Year 1978
Number of shared co-authors 8
William E Grizzle
University of Alabama at Birmingham
Career Start Year 1974
Number of shared co-authors 8
Paul S Meltzer
Center for Cancer Research, National Cancer Institute, National Institutes of Health
Career Start Year 1970
Number of shared co-authors 36
J. Carl Barrett
Oncology R&D
Career Start Year 1966
Number of shared co-authors 11

Collaborators

Jean-Pierre J Issa
Fels Cancer Institute for Personalized Medicine, Temple University School of Medicine
Co-authored papers 38
Kornel E Schuebel
National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health
Co-authored papers 30
Leander Van Neste
Maastricht University Medical Center
Co-authored papers 22
Leslie Cope
Johns Hopkins University School of Medicine
Co-authored papers 16
David N Watkins
Research Institute in Oncology and Hematology
Co-authored papers 15
Kurtis E Bachman
Co-authored papers 14
Joyce E Ohm
Roswell Park Comprehensive Cancer Center
Co-authored papers 12
Nancy E Davidson
Co-authored papers 12
Manon van Engeland
Maastricht University Medical Center
Co-authored papers 12
Feyruz V Rassool
University of Maryland Greenebaum Comprehensive Cancer Center
Co-authored papers 11
Timothy A Chan
Cleveland Clinic.
Co-authored papers 10
Helai P Mohammad
Collegeville
Co-authored papers 10
Wei Zhang
Montefiore Medical Center
Co-authored papers 8
Afshin Beheshti
Co-authored papers 8
Victor E Velculescu
Co-authored papers 7
Hui Shen
Van Andel Institute
Co-authored papers 7
Bert Vogelstein
Co-authored papers 7
Peter W Laird
Van Andel Institute
Co-authored papers 7
Wim Van Criekinge
Ghent University
Co-authored papers 7
Daniel J Weisenberger
Co-authored papers 7
Charles M Rudin
Memorial Sloan Kettering Cancer Center
Co-authored papers 6
Cem Meydan
Co-authored papers 6
Qing Kay Li
Co-authored papers 6
Douglas C Wallace
Co-authored papers 6
Jonathan Foox
Co-authored papers 6
Deanne Taylor
Co-authored papers 6
John D Minna
University of Texas Southwestern Medical Center at Dallas
Co-authored papers 5
Wayne Yu
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Co-authored papers 5
Jonathan C Schisler
Co-authored papers 5
William Marston Linehan
Co-authored papers 5
Release 1.2